MRO Magazine

Ceapro appoints senior VP of Technical Operations

April 28, 2023 | By MRO staff

Ceapro Inc., a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, has appoined of Michel (Mitch) Regnier as senior vice-president, technical operations.

Regnier is an operations executive and professional engineer with over 20 years of technical and leadership experience in the medical device, pharmaceutical and aerospace materials manufacturing industries.

In this role, Regnier will be responsible for the management and growth of the bioprocessing business unit (Ceapro’s profitable base business), the implementation of a product development department, the maintenance of equipment and buildings and the management of the technology development department with a major emphasis on the implementation of a pilot scale unit of the PGX Technology at the Agri Food Discovery Place in Edmonton.


“We are very pleased to welcome Mitch to our team and bolster our efforts to develop new products and unique technologies. His extensive managerial experience along with his unique skillset and expertise well-positions us to lead the scale up of our disruptive technologies in preparation for commercialization of products and the signing of partnerships to unlock further potential. We continue to focus our efforts on propelling Ceapro into its next phase of growth as a biopharmaceutical company and believe this is another step forward in building momentum,” said Gilles Gagnon, M.Sc., MBA, president and CEO, Ceapro.

Prior to joining Ceapro, Regnier served in a number of roles at Oerlikon Metco (Canada) Inc., a subsidiary of OC Oerlikon AG, a global provider of industrial technology based in Switzerland, with a focus on manufacturing materials, primarily nickel-based metal powders

“This is an exciting time in the company’s history with the potential to generate growing value in the near and long term,” said Regnier. “I look forward to completing the development of technologies such as PGX, that continue to demonstrate its ability to successfully generate novel bioactive delivery systems at a quality that no other known technologies have been able to generate. I am excited to join the team at Ceapro and look forward to assisting in executing the Company’s strategic plans.”


Stories continue below

Print this page